[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100601404":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":33,"centralContacts":38,"locations":45,"responsibleParty":59,"collaborators":43,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":43,"eligibilityCriteria":68,"healthyVolunteers":64,"sex":69,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":43,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":43,"overallStatus":48,"whyStopped":43,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"National Cancer Institute, Egypt","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"nalbuphine (group A)","ACTIVE_COMPARATOR","group A (nalbuphine) will receive a single dose of nalbuphine (0.2 mg\u002Fkg) immediately after surgery to be repeated every 8 hours for the duration of the study (72 hours)",[13],"Drug: Nalbuphine",{"label":15,"type":10,"description":16,"interventionNames":17},"Tramadol (group B)","group B( Tramadol) will receive a single dose of tramadol (2 mg\u002Fkg) immediately after surgery to be repeated every 8 hours for the duration of the study (72 hours).",[18],"Drug: Tramadol",[20,27],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Nalbuphine","this group will a single dose of nalbuphine (0.2 mg\u002Fkg) immediately after surgery to be repeated every 8 hours for the duration of the study (72 hours)",[9],[26],"nalufin",{"type":21,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"Tramadol","this group will receive a single dose of tramadol (2 mg\u002Fkg) immediately after surgery to be repeated every 8 hours for the duration of the study (72 hours).",[15],[32],"tramal",[34],{"name":35,"affiliation":36,"role":37},"Reham mohamed gamal, MD","assistant professor","PRINCIPAL_INVESTIGATOR",[39],{"name":40,"role":41,"phone":42,"phoneExt":43,"email":44},"Norma Osama AbdAllah Zayed, MD","CONTACT","01067843111",null,"norma.osama@nci.cu.edu.eg",[46],{"facility":47,"status":48,"city":49,"state":43,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":43},"National cancer institute","RECRUITING","Cairo","11769","Egypt","EG",{"type":54,"coordinates":55},"Point",[56,57],31.24967,30.06263,{"lat":57,"lon":56},{"type":37,"investigatorFullName":60,"investigatorTitle":61,"investigatorAffiliation":5,"oldNameTitle":43,"oldOrganization":43},"Norma Osama Abdalla Zayed","Lecturer of Anesthesia, Surgical ICU and Pain Management, National Cancer Institute, Cairo University","100601404","nalbuphine-versus-tramadol-on-post-operative-analgesia-in-abdominal-surgery-on-pediatric-cancer-patient-100601404",false,"NCT07110051","Nalbuphine Versus Tramadol on Post Operative Analgesia in Abdominal Surgery on Pediatric Cancer Patient","Comparative Study Between Nalbuphine Versus Tramadol on Post Operative Analgesia in Abdominal Surgery on Pediatric Cancer Patient","Inclusion Criteria:\n\n* Participants will be children aged 3-12 years\n* American society of anesthesia (ASA) classification I-III.\n* scheduled for elective Abdominal surgery under general anesthesia\n\nExclusion Criteria:\n\n* child guardian refusal.\n* Allergy from Tramal or nalbuphine\n* Patient with previous chronic pain on opioids","ALL","3 Years","12 Years",{"count":73,"type":74},128,"ESTIMATED","INTERVENTIONAL",[77],"NA","In current study the investigators aim to compare between nalbuphine versus tramadol for post-operative pain control in abdominal surgeries in pediatric.",[28,22,80,81],"Abdominal Surgeries","Pediatric Cancer","2025-08-06",{"date":84,"type":85},"2025-08-11","ACTUAL",{"date":87,"type":85},"2025-01-15",{"date":89,"type":74},"2025-10-15",{"name":5,"class":6},1]